In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Kiadis Pharma N.V.

http://www.kiadis.com

Latest From Kiadis Pharma N.V.

Re-Focused Kiadis Preps Trials With Natural Killer Cells

Kiadis Pharma’s CEO says its processed natural kill cell therapies can improve hematopoietic stem cell transplants and also treat resurgent leukemia.

Clinical Trials Commercial

Finance Watch: Big Money For Big Goals Met By Reata, CRISPR, Karuna

Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.

Financing Business Strategies

Roche’s Polivy Among Seven New Drugs On Track For EU-Wide Approval

Seven drugs, including two orphans and two generics, are on track to receive pan-EU approval.

Europe Approvals

Jumping Before They Were Pushed – Kiadis And Aradigm Withdraw EU Filings

Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP. 

Drug Review Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Celmed BioSciences, Inc.
    • Kiadis Pharma B.V.
UsernamePublicRestriction

Register